압셀러라 바이올로직스(ABCL)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $12.53 (-1.57%), 시가총액 $1.40B, 52주 최저~최고 $1.97 ~ $6.17.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was
압셀러라 바이올로직스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
압셀러라 바이올로직스의 현재 주가는 $12.53 (-1.57%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
압셀러라 바이올로직스의 시가총액은 약 $1.40B입니다.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medic